The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | SOUNDTRACK-B: a Phase II study of surovatamig in R/R B-cell non-Hodgkin lymphoma
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, briefly discusses the SOUNDTRACK-B study (NCT06526793), a Phase II single-arm trial evaluating the efficacy and safety of surovatamig (AZD0486) in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Dr Cheah highlights that the trial is ongoing, with cohorts open for both follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
SOUNDTRACK-B is another Trial in Progress abstract. It’s evaluating the novel CD19/CD3 bispecific antibody AZD0486, now known as surovatamig, in patients with relapsed/refractory follicular or diffuse large B-cell lymphoma. So this trial is ongoing, and again, because it’s a Trial in Progress abstract, we don’t have any results to share other than to say that we do have cohorts open in both follicular and diffuse large B-cell lymphoma...
SOUNDTRACK-B is another Trial in Progress abstract. It’s evaluating the novel CD19/CD3 bispecific antibody AZD0486, now known as surovatamig, in patients with relapsed/refractory follicular or diffuse large B-cell lymphoma. So this trial is ongoing, and again, because it’s a Trial in Progress abstract, we don’t have any results to share other than to say that we do have cohorts open in both follicular and diffuse large B-cell lymphoma. There is fixed-duration therapy with surovatamig, which is given by intravenous administration, and we are seeing also at this congress updated results from the Phase Ib experience in both of these diseases showing pretty encouraging response rates. So we are continuing to treat patients in Phase II, and the study continues.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
